A complete list of drug interactions for Retatrutide is not yet available
Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database
Most compounded GLP-1 options are not covered by insurance
This data suggests that more healthcare providers are seeing the benefits of these medications for treating obesity, which is a significant public health shift, Yee Hui Yeo, MD, a clinical fellow in the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai and co-first author of the study said in a press release
Federal law prohibits Medicare from covering drugs solely for weight loss, meaning GLP-1s are only reimbursed under Part D for other approved indications, like type 2 diabetes, cardiovascular risk reduction, MASH, or sleep apnea
In the absence of high-quality studies, the diagnostic and therapeutic approach proposed is based on the consensus of experts of the Grupo de Obesidad de la Sociedad Espaola de Endocrinologa y Nutricin [Obesity Group of the Spanish Society of Endocrinology and Nutrition], GOSEEN